Bridgeworth LLC Takes Position in Merck & Co., Inc. (NYSE:MRK)
Bridgeworth LLC Takes Position in Merck & Co., Inc. (NYSE:MRK)
Bridgeworth LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK – Get Rating) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,518 shares of the company's stock, valued at approximately $207,000.
Bridgeworth LLC在第一季度購買了默克公司(NYSE：MRK-GET Rating)的新股，據該公司最近向美國證券交易委員會(Securities And Exchange Commission)披露的情況。該基金購買了2518股該公司股票，價值約20.7萬美元。
A number of other large investors have also recently modified their holdings of MRK. Paulson Wealth Management Inc. boosted its holdings in shares of Merck & Co., Inc. by 1.9% in the 1st quarter. Paulson Wealth Management Inc. now owns 6,144 shares of the company's stock valued at $504,000 after buying an additional 115 shares in the last quarter. Private Management Group Inc. raised its position in shares of Merck & Co., Inc. by 0.4% in the 1st quarter. Private Management Group Inc. now owns 28,832 shares of the company's stock valued at $2,366,000 after purchasing an additional 117 shares during the last quarter. Disciplined Investments LLC raised its position in shares of Merck & Co., Inc. by 24.3% in the 1st quarter. Disciplined Investments LLC now owns 604 shares of the company's stock valued at $50,000 after purchasing an additional 118 shares during the last quarter. Pegasus Asset Management Inc. raised its position in shares of Merck & Co., Inc. by 0.3% in the 1st quarter. Pegasus Asset Management Inc. now owns 34,987 shares of the company's stock valued at $2,871,000 after purchasing an additional 119 shares during the last quarter. Finally, Financial Management Professionals Inc. raised its position in shares of Merck & Co., Inc. by 4.1% in the 1st quarter. Financial Management Professionals Inc. now owns 3,123 shares of the company's stock valued at $256,000 after purchasing an additional 123 shares during the last quarter. Institutional investors own 72.88% of the company's stock.
其他一些大型投資者最近也調整了對MRK的持股。鮑爾森財富管理公司(Paulson Wealth Management Inc.)第一季度增持默克公司(Merck&Co.，Inc.)股票1.9%。保爾森財富管理公司在上個季度又購買了115股保爾森財富管理公司的股票，目前持有6,144股該公司股票，價值50.4萬美元。私人管理集團(Private Management Group Inc.)在第一季度將其在默克公司(Merck&Co.，Inc.)股票的持倉增加了0.4%。私人管理集團(Private Management Group Inc.)現在持有該公司28,832股股票，價值2,366,000美元，此前該公司在上個季度又購買了117股。紀律性投資有限責任公司第一季度將其在默克公司股票的持倉量提高了24.3%。紀律投資有限責任公司現在持有604股該公司股票，價值5萬美元，在上個季度又購買了118股。飛馬資產管理公司(Pegasus Asset Management Inc.)第一季度將其在默克公司(Merck&Co.，Inc.)的股票頭寸提高了0.3%。飛馬資產管理公司現在持有34,987股該公司股票，價值2,871,000美元，該公司在上個季度又購買了119股。最後，Financial Management Offessionals Inc.在第一季度將其在默克公司股票的持倉提高了4.1%。Financial Management Offessionals Inc.在上個季度購買了123股後，現在持有該公司3,123股股票，價值25.6萬美元。機構投資者持有該公司72.88%的股票。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Several equities analysts recently commented on MRK shares. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a "market perform" rating in a research report on Monday, June 27th. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a "neutral" rating to a "buy" rating and increased their price objective for the company from $89.00 to $102.00 in a research report on Wednesday, July 6th. Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They issued a "buy" rating and a $100.00 price objective for the company. Atlantic Securities increased their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, July 13th. Finally, SVB Leerink reissued an "outperform" rating and set a $102.00 price target on shares of Merck & Co., Inc. in a research report on Monday, June 6th. Eight research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $97.44.
幾位股票分析師最近對MRK的股票發表了評論。考恩在6月27日週一的一份研究報告中將默克公司股票的目標價從95美元上調至102.00美元，並給予該公司“市場表現”評級。7月6日，大和資本市場在一份研究報告中將默克公司的股票評級從中性上調至買入，並將該公司的目標價從89美元上調至102.00美元。瑞穗在6月24日星期五的一份研究報告中開始對默克公司的股票進行報道。他們對該公司的評級為“買入”，目標價為100.00美元。大西洋證券在7月13日星期三的一份研究報告中將默克公司股票的目標價從105.00美元上調至110.00美元，並給予該公司“增持”評級。最後，SVB Leerink在6月6日週一的一份研究報告中重新發布了對默克公司的評級，併為默克公司的股票設定了102.00美元的目標價。8名研究分析師對該股的評級為持有，9名分析師給予買入評級，2名分析師給予該股強烈買入評級。根據MarketBeat.com的數據，該公司目前的普遍評級為“適度買入”，平均目標價為97.44美元。
Merck & Co., Inc. Price Performance
默克公司性價比
Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its earnings results on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. The firm had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 50.02%. The business's quarterly revenue was up 28.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. Equities research analysts forecast that Merck & Co., Inc. will post 7.31 EPS for the current year.
默克公司(紐約證券交易所代碼：MRK-GET評級)最近一次公佈收益報告是在7月28日星期四。該公司公佈本季度每股收益為1.87美元，比普遍預期的1.69美元高出0.18美元。該公司本季度營收為145.9億美元，而分析師預期為138.5億美元。默克公司的淨利潤率為29.00%，股本回報率為50.02%。該業務的季度收入同比增長28.0%。去年同期，該公司每股收益為1.31美元。股票研究分析師預計，默克公司本財年每股收益將達到7.31美元。
Merck & Co., Inc. Dividend Announcement
默克公司宣佈分紅
The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Stockholders of record on Thursday, September 15th will be issued a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a dividend yield of 3.16%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio (DPR) is 42.27%.
該公司最近還宣佈了季度股息，將於10月7日(星期五)支付。9月15日(星期四)登記在冊的股東將獲得每股0.69美元的股息。這意味着年化股息為2.76美元，股息收益率為3.16%。本次股息除息日為9月14日星期三。默克公司的股息支付率為42.27%。
Merck & Co., Inc. Company Profile
默克公司公司簡介
(Get Rating)
(獲取評級)
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.
默克公司是一家全球性的醫療保健公司。它通過兩個部門運作，製藥和動物健康。製藥部門提供腫瘤學、醫院急性護理、免疫學、神經科學、病毒學、心血管和糖尿病等領域的人類健康藥物產品，以及疫苗產品，如預防性兒科、青少年和成人疫苗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Merck & Co., Inc. (MRK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於默克公司的研究報告(MRK)
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- Beyond Meat不是沒有希望，而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).
想看看還有哪些對衝基金持有MRK嗎？訪問HoldingsChannel.com獲取默克公司(NYSE：MRK-GET Rating)的最新13F文件和內幕交易信息。
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
每天收到默克公司的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對默克公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。